Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $10.19 USD
Change Today -0.08 / -0.78%
Volume 180.5K
VNDA On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 11:50 AM 05/26/15 All times are local (Market data is delayed by at least 15 minutes).

vanda pharmaceuticals inc (VNDA) Snapshot

Open
$10.25
Previous Close
$10.27
Day High
$10.48
Day Low
$10.10
52 Week High
06/30/14 - $16.50
52 Week Low
10/13/14 - $8.34
Market Cap
426.3M
Average Volume 10 Days
788.6K
EPS TTM
$-2.35
Shares Outstanding
41.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for VANDA PHARMACEUTICALS INC (VNDA)

vanda pharmaceuticals inc (VNDA) Related Businessweek News

No Related Businessweek News Found

vanda pharmaceuticals inc (VNDA) Details

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The company’s products include HETLIOZ, a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt, a product for the treatment of schizophrenia. Its products also include Tradipitant, a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis; Trichostatin A, a small molecule histone deacetylase inhibitor; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

64 Employees
Last Reported Date: 03/13/15
Founded in 2002

vanda pharmaceuticals inc (VNDA) Top Compensated Officers

Founder, Chief Executive Officer, President a...
Total Annual Compensation: $580.0K
Chief Financial Officer, Senior Vice Presiden...
Total Annual Compensation: $360.0K
Chief Medical Officer and Senior Vice Preside...
Total Annual Compensation: $360.0K
Compensation as of Fiscal Year 2014.

vanda pharmaceuticals inc (VNDA) Key Developments

Vanda Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM

Vanda Pharmaceuticals, Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-13-2015 02:20 PM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Mihael H. Polymeropoulos, Founder, Chief Executive Officer, President and Director.

Vanda Pharmaceuticals Inc. Reports Consolidated Financial Results for the First Quarter Ended March 31, 2015; Reaffirms Earnings Guidance for 2015

Vanda Pharmaceuticals Inc. reported consolidated financial results for the first quarter ended March 31, 2015. Total revenues for the first quarter of 2015 were $22.2 million, compared to $9.1 million for the first quarter of 2014. Loss from operations was $10.3 million against $26.6 million last year. Net loss was $10.2 million or $0.24 per basic and diluted share against $26.5 million or $0.79 per basic and diluted share last year. Total net product sales increased by 268% over the prior quarter, driven by the growth in HETLIOZ® sales and the acquisition of the Fanapt® product rights. Non-GAAP net loss was $4.1 million or $0.10 per basic and diluted share against $32.0 million or $0.95 per basic and diluted share last year. Non-GAAP total revenues were $22.2 million, compared to $1.7 million for the first quarter of 2014.  The company reaffirmed full year of 2015 net product sales guidance of $95 million to $110 million. The company expects intangible asset amortization expense of $13.0 million.

Vanda Pharmaceuticals, Inc. Receives Positive CHMP Opinion for Hetlioz (Tasimelteon) for the Treatment of Non-24-Hour Sleep-Wake Disorder in the European Union

Vanda Pharmaceuticals, Inc. announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending approval of HETLIOZ(tasimelteon) for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) in totally blind adults in the European Union (EU). The CHMP positive opinion will be reviewed by the European Commission (EC). If approved, the EC grants a centralized marketing authorization with unified labeling that is valid in the 28 countries that are members of the EU, as well as European Economic Area members Iceland, Liechtenstein and Norway. The EC usually issues a final decision within two months of a CHMP opinion.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VNDA:US $10.19 USD -0.08

VNDA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AstraZeneca PLC 4,374 GBp -100.00
Bristol-Myers Squibb Co $67.51 USD -0.79
Eli Lilly & Co $74.21 USD -0.09
Pernix Therapeutics Holdings Inc $6.30 USD -0.08
Sanofi €90.64 EUR -0.69
View Industry Companies
 

Industry Analysis

VNDA

Industry Average

Valuation VNDA Industry Range
Price/Earnings 10.9x
Price/Sales 6.8x
Price/Book 2.8x
Price/Cash Flow 10.1x
TEV/Sales 4.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VANDA PHARMACEUTICALS INC, please visit www.vandapharmaceuticals.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.